
FibroGen (FGEN) Stock Forecast & Price Target
FibroGen (FGEN) Analyst Ratings
Bulls say
FibroGen Inc. focuses on developing therapeutics for serious medical needs, generating most of its revenue through collaboration agreements, primarily in Europe and Japan. The anticipated extension of the company's cash runway significantly enhances its financial health, providing confidence amid challenging macroeconomic conditions. This strong cash position allows FibroGen to advance its clinical trials, particularly for FG-3246, without anticipated interruptions, which supports a favorable outlook for the company's growth and sustainability.
Bears say
FibroGen Inc's financial outlook is negatively influenced by several critical factors, including the potential for failed or inconclusive clinical trials that could hinder product development. The company also faces challenges in securing adequate funding, which is essential for progressing its product candidates, and may encounter dilutive capital raises that could further impact shareholder value. Additionally, the lack of commercial success and the risk of being delisted pose significant threats to the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.
FibroGen (FGEN) Analyst Forecast & Price Prediction
Start investing in FibroGen (FGEN)
Order type
Buy in
Order amount
Est. shares
0 shares